Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 1,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Regimen Clear all

Conditions: Obstetric Labour, Premature
Interventions: Retosiban IV infusion, Placebo IV infusion; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 45 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 33
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 29 more

Conditions: Influenza
Interventions: Favipiravir, Placebo comparator; Drug
Lead sponsor: MDVI, LLC; Industry
Eligibility: 20 Years to 80 Years
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 148
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 118 more

Conditions: Refractory Mixed Type Melasma
Interventions: Q-Switched Nd:YAG Laser (RevLite), Retin-A and microdermabrasion; Device · Drug
Lead sponsor: ConBio, a Cynosure Company; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Fatigue
Interventions: Fisetin followed by Placebo, Placebo followed by Fisetin; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 65 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Opioid Use, Fractures, Bone, Trauma
Interventions: Narcotic pain medication, Nonnarcotic pain medications; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: COVID-19
Interventions: Remdesivir, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Apremilast, dornase alfa, Celecoxib, Famotidine, IC14, Aviptadil, narsoplimab, Cyproheptadine, Cyclosporine; Drug · Biological
Lead sponsor: QuantumLeap Healthcare Collaborative; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 36
States / cities: Birmingham, Alabama • Davis, California • Irvine, California + 30 more

Conditions: Polymyalgia Rheumatica
Interventions: Secukinumab 300 mg, Secukinumab 150 mg, Placebo to secukinumab; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years to 100 Years
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 22
States / cities: Avondale, Arizona • Peoria, Arizona • Phoenix, Arizona + 17 more

Conditions: Extensive-stage Small Cell Lung Cancer
Interventions: Obatoclax, Carboplatin/etoposide; Drug
Lead sponsor: Gemin X; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 32
States / cities: Huntsville, Alabama • Muscle Shoals, Alabama • Scottsdale, Arizona + 27 more

Conditions: Diabetes Mellitus
Interventions: AMG 151, Placebo, Metformin; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 65
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 57 more

Conditions: Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions: Efinopegdutide 20 mg/mL, Semaglutide 1.34 mg/mL; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 9
States / cities: Montclair, California • Hialeah, Florida • Miami Lakes, Florida + 5 more

Conditions: Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
Interventions: Faricimab, Aflibercept, Sham Procedure; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 57
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 52 more

Conditions: Parkinson's Disease (Disorder)
Interventions: IR CD-LD, IPX203 ER CD-LD, Placebo Matching IPX203, Placebo Matching IR CD-LD; Drug · Other
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 40 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 56
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 46 more

Conditions: Hepatitis B, Cirrhosis, Liver, Chronic Liver Disease
Interventions: Heplisav-B Injectable Product, 2-dose regimen, Heplisav-B Injectable Product, 3-dose regimen; Biological
Lead sponsor: Mercy Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Heart Failure
Interventions: Remote Ischemic Conditioning (using Sphygmomanometer); Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions: Placebo, Tanezumab 2.5 mg, Tanezumab 2.5mg/5mg; Other · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 68
States / cities: Birmingham, Alabama • Phoenix, Arizona • Surprise, Arizona + 54 more

Conditions: COPD, Acute Respiratory Failure
Interventions: Revefenacin Inhalation Solution [Yupelri], Ipratropium Bromide; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 40 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: Los Angeles, California • Santa Monica, California

Conditions: Lung Neoplasm, Carcinoma Non-small Cell Lung Cancer Stage IIIA, Carcinoma Non-small Cell Lung Cancer Stage IIIB, Carcinoma Non-small Cell Lung Cancer Stage IV
Interventions: Lucanix™, Placebo Comparator; Biological · Other
Lead sponsor: NovaRx Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 53
States / cities: Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 46 more

Conditions: Healthy
Interventions: Dasatinib, Quercetin, Fisetin; Drug
Lead sponsor: Sundeep Khosla, M.D.; Other
Eligibility: 60 Years and older · Female only
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostatectomy
Interventions: Exercise; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Amyotrophic Lateral Sclerosis
Interventions: SLS-005, Matching Placebo; Drug
Lead sponsor: Merit E. Cudkowicz, MD; Other
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Malaria
Interventions: BNT165c, BNT165d, Placebo; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 163 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more

Conditions: Healthy
Interventions: Dimethyl Fumarate (BG00012), Aspirin, BG00012 matching placebo, ASA matching placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Prostatic Hyperplasia
Interventions: ML-04A; Drug
Lead sponsor: Milkhaus Laboratory; Industry
Eligibility: 45 Years to 80 Years · Male only
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 14
States / cities: Mobile, Alabama • Fair Oaks, California • Stanford, California + 11 more

Conditions: Snakebites, Envenoming, Envenoming, Snake, Envenomation, Snake
Interventions: Varespladib Methyl, Placebo, Standard of care (SOC); Drug
Lead sponsor: Ophirex, Inc.; Industry
Eligibility: 5 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Tucson, Arizona • Loma Linda, California • Jacksonville, Florida + 5 more

Search by objective public record fields.

A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor

Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza

Study of Laser Treatment of Melasma

Pilot Study of Fisetin to Improve Fatigue Among Older Adult Cancer Survivors

Nonopioid Pain Control Regimen After Open Reduction and Internal Fixation of Traumatic Fractures

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)

AMG 151 Amgen Protocol Number 20100761

A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

The IMPULSE Study: Pilot

Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee

Revefenacin in Acute Respiratory Insufficiency in COPD

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans

Exercise Training Among Men With Prostate Cancer

HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

Alternate Dosing Regimens of BG00012 in Healthy Volunteers

A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).

Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite